Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Oncology FDA Approval
Oncology Drug Approval News Flash: Vimseltinib (Romvimza) Approved by FDA for Tenosynovial Giant Cell Tumor (TGCT)
【FDA Approval Alert】Deciphera's vimseltinib (Romvimza) Approved for TGCT (February 14, 2025) On February 14, 2025, the U.S. FDA approved vimseltinib (Romvimza) for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) wh... -
Oncology FDA Approval
Oncology Drug Approval News Flash: Brentuximab Vedotin + Lenalidomide + Rituximab Combination Receives Accelerated FDA Approval for R/R LBCL
【FDA Approval Alert】Seagen's brentuximab vedotin combination Approved for Relapsed/Refractory Large B-Cell Lymphoma (LBCL) (February 11, 2025) On February 11, 2025, the U.S. FDA granted accelerated approval to brentuximab vedotin (Adce... -
Oncology FDA Approval
Oncology Drug Approval News Flash: Mirdametinib (Gomekli) Approved by FDA for NF1-Associated Plexiform Neurofibromas
【FDA Approval Alert】SpringWorks's mirdametinib (Gomekli) Approved for NF1-Associated Plexiform Neurofibromas (February 11, 2025) On February 11, 2025, the U.S. FDA approved mirdametinib (Gomekli) for patients aged 2 years and older wit... -
Oncology FDA Approval
Oncology Drug Approval News Flash: Fam-trastuzumab deruxtecan-nxki (Enhertu) Approved by FDA for HER2-Low and Ultralow Breast Cancer
【FDA Approval Alert】Daiichi Sankyo's Enhertu Approved for HER2-Low and Ultralow Breast Cancer (January 27, 2025) On January 27, 2025, the U.S. FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with unresectable or metas... -
Oncology FDA Approval
Oncology Drug Approval News Flash: Datopotamab Deruxtecan-dlnk (Datroway) Approved by FDA for HR-Positive, HER2-Negative Breast Cancer
【FDA Approval Alert】Daiichi Sankyo's Datroway Approved for HR-Positive, HER2-Negative Breast Cancer (January 17, 2025) On January 17, 2025, the U.S. FDA approved datopotamab deruxtecan-dlnk (Datroway) for adults with unresectable or me... -
Pharma & Biotech News
2025 Therapeutics Trend: 3 Battlegrounds Defining the Year (Obesity / ADC / Rare Disease)
What are the trends in therapeutics and market launch drugs in 2025? Market Expansion and Contested Competition for Obesity Drugs ADC Wave and Next Generation ADC (Antibody Drug Conjugate) Challenges for Rare Disease Therapeutic Roles an...